ABL1 and acute lymphoblastic leukemia: Taken together, our study provide clear evidence of a functional interplay between BCR/ABL and ABL/BCR in the pathogenesis of Ph+ ALL, which suggest an additional target to be hidden by molecular therapy approaches in order to achieve an efficient treatment of this high risk subgroup of ALL.